Kai Yu, Noorie Hyun, Barbara Fetterman, Thomas Lorey, Tina R Raine-Bennett, Han Zhang, Robin E Stamps, Nancy E Poitras, William Wheeler, Brian Befano, Julia C Gage, Philip E Castle, Nicolas Wentzensen, Mark Schiffman
Background: State-of-the-art cervical cancer prevention includes human papillomavirus (HPV) vaccination among adolescents and screening/treatment of cervical precancer (CIN3/AIS and, less strictly, CIN2) among adults. HPV testing provides sensitive detection of precancer but, to reduce overtreatment, secondary "triage" is needed to predict women at highest risk. Those with the highest-risk HPV types or abnormal cytology are commonly referred to colposcopy; however, expert cytology services are critically lacking in many regions...
April 11, 2018: Journal of the National Cancer Institute